Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Return on Capital Employed (2023 - 2025)

Historic Return on Capital Employed for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to 0.02%.

  • Monte Rosa Therapeutics' Return on Capital Employed rose 4700.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 4700.0%. This contributed to the annual value of 0.38% for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Return on Capital Employed stood at 0.02%, which was up 4700.0% from 0.04% recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Return on Capital Employed high stood at 0.04% for Q2 2025, and its period low was 0.62% during Q4 2023.
  • Moreover, its 3-year median value for Return on Capital Employed was 0.41% (2024), whereas its average is 0.31%.
  • Per our database at Business Quant, Monte Rosa Therapeutics' Return on Capital Employed skyrocketed by 2500bps in 2024 and then surged by 5800bps in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Return on Capital Employed (Quarter) stood at 0.62% in 2023, then surged by 40bps to 0.37% in 2024, then surged by 107bps to 0.02% in 2025.
  • Its Return on Capital Employed stands at 0.02% for Q3 2025, versus 0.04% for Q2 2025 and 0.01% for Q1 2025.